Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.74 |
| ▸ | JAK2 | O60674 | 4/20 | 0.74 |
| ▸ | SRC | P12931 | 3/20 | 0.74 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.74 |
| ▸ | JAK3 | P52333 | 7/20 | 0.74 |
| ▸ | EGFR | P00533 | 3/20 | 0.73 |
| ▸ | JAK1 | P23458 | 1/20 | 0.73 |
| ▸ | TTK | P33981 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | TXK | P42681 | 1/20 | 0.73 |
| ▸ | BLK | P51451 | 1/20 | 0.73 |
| ▸ | BTK | Q06187 | 1/20 | 0.73 |
| ▸ | ITK | Q08881 | 1/20 | 0.73 |
| ▸ | INSR | P06213 | 4/20 | 0.67 |
| ▸ | IGF1R | P08069 | 4/20 | 0.67 |
| ▸ | AXL | P30530 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | CCNK | O75909 | 1/20 | 0.63 |
| ▸ | CCND3 | P30281 | 1/20 | 0.63 |
| ▸ | CDK9 | P50750 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255239 | 0.93 | JAK3 (0.76) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL24255248 | 0.92 | JAK3 (0.64) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL24255221 | 0.92 | JAK3 (0.75) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL24255241 | 0.92 | JAK3 (0.75) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL24255220 | 0.91 | JAK3 (0.74) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL24258099 | 0.89 | JAK3 (0.71) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL17205279 | 0.88 | EGFR (0.72) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL24255242 | 0.86 | ALK (0.70) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL17209775 | 0.85 | JAK3 (0.85) | ALKJAK2SRCTNK2JAK3 | |
| SCHEMBL17209825 | 0.85 | JAK3 (1.00) | JAK2JAK3EGFRJAK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-21 | — | — | US | disclosed |
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-21 | — | — | US | disclosed |
| WO-2022036312-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | ALK 272/4885JAK2 604/4885SRC 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.